SearchTodayMainsPrelimsSubjectCSAT

Science Budget: Ambitious Goals with Persistent Gaps

Though the budget showcases significant investments in science sectors, core funding issues and delays threaten basic research and state universities.
G
Gopi
••5 mins read
Budget’s Science Push Faces Funding Reality Check
Not Started

1. Budget Vision vs. Ground Reality in Science Funding

The Union Budget 2026–27 positions science and technology as strategic drivers of economic growth. It highlights major investments in biopharma, semiconductors, critical materials, carbon capture, and mission-linked industrial research. This framing reflects India’s ambition to shift from being a technology adopter to becoming a technology creator.

However, expert assessments reveal a mismatch between stated ambition and administrative delivery. Key scientific departments have faced consistent under-spending and mid-year budget cuts. Fluctuating fund flow, administrative transitions, and delays in new institutional structures dilute the intended impact of large announcements.

India’s research ecosystem has struggled with weak financial predictability. Sharp disparities between Budget Estimates (BE), Revised Estimates (RE), and Actual Expenditure indicate systemic challenges. In 2023–24, the Department of Biotechnology fell from ₹2,683.86 crore (BE) to ₹1,467.34 crore (Actuals); the Department of Science and Technology declined from ₹7,931.05 crore (BE) to ₹4,002.67 crore (Actuals). Such volatility affects long-term research planning.

Inconsistent funding also undermines translational capacity, where laboratories, universities, and industry depend on predictable cashflows. Without addressing administrative bottlenecks, India’s aspiration for mission-mode innovation will remain constrained.

Stable financing is a foundational requirement for research ecosystems; when fund flows remain unpredictable, even well-designed missions risk devolving into paper proposals rather than functional programmes.

2. Biopharma SHAKTI: Promise and Structural Risks

Biopharma SHAKTI is the budget’s flagship programme: ₹10,000 crore over five years. It aims to scale indigenous biologics, biosimilars, and platforms targeting non-communicable diseases. Officials link it to past successes such as the DBT–National Biopharma Mission and propose expansions into gene therapy, biomanufacturing hubs, and AI–biology integration (“Moolankur” hubs).

Yet experts emphasise that mission success depends on upstream scientific infrastructure. The concern is that implementing the programme primarily through the Department of Pharmaceuticals may privilege manufacturing outputs over early-stage research. This risks narrowing India’s innovation funnel to late-stage industrial scaling while neglecting idea-generation pipelines in universities and research labs.

Recent administrative transitions—from SERB to the Anusandhan National Research Foundation—have already introduced significant funding disruptions. Poorly coordinated missions could further isolate foundational life-science research, which underpins industrial biotech capabilities.

“If Biopharma SHAKTI is administered primarily through the Department of Pharmaceuticals… it could privilege downstream manufacturing while neglecting the upstream ecosystem.” — L.S. Shashidhara

Science missions require an ecosystem approach; when downstream manufacturing overshadows upstream research, long-term competitiveness declines even if short-term outputs appear robust.

3. Mission-Mode Infrastructure: Opportunity with Gaps

The budget emphasises large-scale infrastructure: semiconductor fabrication, CCUS technologies, critical materials processing, and advanced electronics manufacturing. Institutions like CSIR view this as affirmation of science’s role in national growth and self-reliance.

Such missions can consolidate India’s technological strengths by integrating research networks, clinical trial platforms, and multi-sector innovation hubs. They can also enhance “full-stack” capabilities—moving from discovery to design to deployment—especially in sectors like diagnostics and nanoengineering.

However, the budget mainly outlines policy intent rather than secured financial pathways. Experts note that sector-specific allocations for these missions are expected only in following years, continuing a pattern where mission rhetoric precedes mission funding. India’s R&D spending remains at 0.64–0.7% of GDP, stagnant in real terms.

Long delays in operationalising promised funds—such as the ₹1 lakh crore research corpus announced in 2024–25, of which only ₹3,000 crore has been disbursed—raise concerns about delivery credibility.

Mission-mode investment expands national capacity only when funds are timely, multi-year, and shielded from administrative lags; if not, missions risk becoming aspirational frameworks rather than functional catalysts.

4. Basic Research vs. Applied Science: A Growing Imbalance

A core concern is the widening gap between applied and basic research funding. While applied sectors such as semiconductors, space applications, and biotech manufacturing receive strong political support, foundational sciences face stagnation. The Indian Institute of Astrophysics and other autonomous institutions receive limited allocations (totaling ₹1,623 crore) despite proposals to upgrade major national facilities worth ₹3,500 crore.

Basic research contributes long-term strategic value—instrumentation, algorithms, imaging systems, and precision measurement technologies that seed future industries. Experts warn that targeting only fashionable high-tech sectors risks hollowing the upstream innovation landscape.

“The budget follows a globally fashionable script privileging applied sectors while underfunding basic research.” — C.P. Rajendran

India’s reliance on future private-sector R&D contribution remains optimistic; private investment in domestic R&D has not grown to the required scale. State underinvestment therefore directly restricts scientific sovereignty.

Neglecting basic research weakens the discovery pipeline; without foundational science, applied innovations lose depth, resilience, and long-term competitiveness.

5. Universities, Human Capital, and Structural Reform

The budget introduces “university townships” to integrate industry with education. While conceptually aligned with the NEP 2020 vision of multidisciplinary learning, experts caution that bypassing legacy State universities could be counterproductive. These institutions educate over 80% of India’s students and have historically anchored regional research ecosystems.

A thematic cluster model—where State universities lead foundational disciplines while technical institutes contribute specialised tools—may offer a more balanced and inclusive approach. Such structures leverage existing capacities rather than creating isolated enclaves with limited regional integration.

Sustained investment in routine small- and medium-sized research grants is crucial. These grants often deliver high social returns by supporting early-career researchers, regional laboratories, preventive public-health research, and grassroot innovation.

Human capital and institutional depth are cumulative assets; if new enclaves replace rather than strengthen legacy institutions, India risks fragmenting its research ecosystem instead of expanding it.

Conclusion

The Union Budget 2026–27 outlines an ambitious, mission-driven vision for Indian science, signalling aspirations for technological sovereignty and accelerated industrial innovation. However, the effectiveness of this vision depends on consistent funding, institutional autonomy, and balanced support for both basic and applied research. Strengthening universities, ensuring timely fund flow, and safeguarding upstream scientific ecosystems are essential for converting mission rhetoric into sustained national capacity. Long-term developmental outcomes will hinge on whether India can build a predictable, transparent, and inclusive science funding architecture that aligns ambition with delivery.

Quick Q&A

Everything you need to know

The Union Budget 2026-27 signals a strategic shift in India’s development trajectory—from being primarily a technology adopter to aspiring as a technology creator. This is evident in mission-mode allocations for biopharma, semiconductors, carbon capture, critical minerals, and research-linked industrial finance. The emphasis is on building domestic capabilities in frontier sectors that have high strategic and economic value.

Programmes such as Biopharma SHAKTI (₹10,000 crore over five years) and India Semiconductor Mission 2.0 reflect a push towards strengthening indigenous R&D, manufacturing ecosystems, and translational research infrastructure. These initiatives align with broader goals of self-reliance, supply chain resilience, and global competitiveness.

However, the transition is constrained by execution challenges. Past trends of downward revisions in science allocations and under-spending suggest that ambition alone is insufficient. Sustainable technology creation requires predictable funding, institutional autonomy, and effective governance mechanisms.

Scientific research operates on long timelines and depends heavily on continuity. Frequent reductions from Budget Estimates (BE) to Revised Estimates (RE), as seen in the Departments of Biotechnology and Science & Technology, disrupt project cycles, delay procurement, and weaken institutional morale. Such uncertainty particularly harms early-career researchers and small grant recipients.

Administrative disruptions—such as the transition from the Science and Engineering Research Board to the Anusandhan National Research Foundation—have compounded these challenges. While reforms aim to streamline governance, delays in fund disbursement undermine credibility and slow innovation output.

For mission-mode programmes like Biopharma SHAKTI to succeed, smooth coordination between the Finance Ministry, line departments, and research agencies is essential. Without predictable financing, India risks weakening the very ecosystem it seeks to strengthen.

The Budget’s strong focus on applied sectors—such as semiconductors, space applications, CCUS, and electronic manufacturing—mirrors global trends where governments prioritize commercially viable, high-visibility sectors. Such investments can generate employment, exports, and technological self-reliance in the short to medium term.

However, critics argue that excessive focus on applied missions risks underfunding basic science, which forms the intellectual foundation for future breakthroughs. For instance, fundamental research in solid-state physics enabled today’s semiconductor industry. Similarly, astronomy research has historically produced spin-offs like CCD imaging and communication technologies.

With India’s GERD hovering around 0.64–0.7% of GDP, stagnation in funding for autonomous institutes could weaken long-term innovation capacity. A balanced funding architecture—supporting both curiosity-driven and mission-driven research—is essential for sustainable scientific growth.

Biopharma SHAKTI aims to scale indigenous biologics and biosimilars while addressing non-communicable diseases. To avoid privileging downstream manufacturing alone, its governance must integrate the broader life sciences ecosystem—universities, research institutes, start-ups, and clinical networks.

A comprehensive approach would include:

  • Support for small and medium research grants to sustain upstream discovery science
  • Creation of biomanufacturing hubs and AI-integrated biofoundries
  • Strong collaboration between the Department of Pharmaceuticals and DBT

For example, linking laboratory discoveries in cell and gene therapy to industrial-scale production facilities can create a seamless innovation pipeline. Such integration ensures ecosystem-wide strengthening rather than isolated sectoral gains.

One major reason is administrative bottlenecks. Large innovation funds, such as the promised ₹1 lakh crore Research, Development and Innovation Fund, often face delays due to inter-ministerial coordination, compliance procedures, and cautious financial oversight. As noted, only a fraction of announced funds has been disbursed.

Fiscal pressures also contribute. In times of revenue constraints, research allocations may be revised downward because their outcomes are long-term and less politically visible compared to welfare schemes.

Additionally, expectations that private capital will significantly supplement public R&D have not materialised at scale. High-risk, long-gestation research areas often require strong public investment signals to crowd in private participation.

Legacy State universities educate over 80% of India’s students and possess deep strengths in basic sciences and humanities. Rather than bypassing them through elite ‘university townships’, policymakers could adopt a thematic cluster model where State universities lead foundational research while technical institutes contribute advanced tools and industry linkages.

For example, a regional innovation cluster could combine a State university’s expertise in agricultural science with an IIT’s biotechnology lab and a local industry partner. Shared infrastructure grants, faculty exchange programmes, and joint doctoral supervision would foster collaboration.

This approach aligns with the National Education Policy 2020’s emphasis on multidisciplinarity and ensures equitable distribution of research capacity. Strengthening legacy institutions is not merely equitable but strategically vital for broad-based national innovation.

Attribution

Original content sources and authors

VM
Vasudevan Mukunth
TH
The Hindu
Sign in to track your reading progress

Comments (0)

Please sign in to comment

No comments yet. Be the first to comment!